Literature DB >> 16081972

Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs.

S García-Bujalance1, C Ladrón de Guevara, J González-García, J R Arribas, A Gutiérrez.   

Abstract

The purpose of this study was to compare a line probe assay (LiPA) with sequence analysis for the detection of mutations conferring resistance to nucleoside and non-nucleoside inhibitors in human immunodeficiency reverse transcriptase and protease inhibitors. The limitations for interpreting LiPA make it unacceptable for routine clinical practice.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16081972      PMCID： PMC1233962          DOI： 10.1128/JCM.43.8.4186-4188.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.

Authors: 
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

2.  Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients.

Authors:  H L Devereux; C Loveday; M Youle; C A Sabin; A Burke; M Johnson
Journal:  AIDS Res Hum Retroviruses       Date:  2000-07-20       Impact factor: 2.205

3.  A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.

Authors:  S Rusconi; S La Seta Catamancio; F Sheridan; D Parker
Journal:  J Clin Virol       Date:  2000-12       Impact factor: 3.168

4.  Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes.

Authors:  Inge Derdelinckx; Kristel Van Laethem; Bart Maes; Yoeri Schrooten; Kirsten De Schouwer; Stéphane De Wit; Katrien Fransen; Sergio García Ribas; Michel Moutschen; Dolores Vaira; Georges Zissis; Marc Van Ranst; Eric Van Wijngaerden; Anne Mieke Vandamme
Journal:  FEMS Immunol Med Microbiol       Date:  2003-11-28

5.  Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.

Authors:  J Servais; C Lambert; E Fontaine; J M Plesséria; I Robert; V Arendt; T Staub; F Schneider; R Hemmer; G Burtonboy; J C Schmit
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Evaluation of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors.

Authors:  M L Villahermosa; G Contreras; L Pérez-Alvarez; F Bru; L Medrano; E Delgado; C Colomo; M Thomson; R Nájera
Journal:  Antivir Ther       Date:  1998

7.  Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.

Authors:  J Martinez-Picado; L Sutton; M P De Pasquale; A V Savara; R T D'Aquila
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

8.  Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations.

Authors:  K Van Laethem; K Van Vaerenbergh; J C Schmit; S Sprecher; P Hermans; V De Vroey; R Schuurman; T Harrer; M Witvrouw; E Van Wijngaerden; L Stuyver; M Van Ranst; J Desmyter; E De Clercq; A M Vandamme
Journal:  J Acquir Immune Defic Syndr       Date:  1999-10-01       Impact factor: 3.731

9.  Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene.

Authors:  L Stuyver; A Wyseur; A Rombout; J Louwagie; T Scarcez; C Verhofstede; D Rimland; R F Schinazi; R Rossau
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

10.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Authors:  Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079
View more
  2 in total

1.  Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.

Authors:  J-H Lee; A Hachiya; S-K Shin; J Lee; H Gatanaga; S Oka; K A Kirby; Y T Ong; S G Sarafianos; W R Folk; W Yoo; S P Hong; S-O Kim
Journal:  Clin Microbiol Infect       Date:  2013-03-11       Impact factor: 8.067

2.  Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.

Authors:  Matthew S Lalonde; Ryan M Troyer; Aslam R Syed; Stanley Bulime; Korey Demers; Francis Bajunirwe; Eric J Arts
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.